A lower limb robotic exoskeleton for home use to enable specially trained individuals with paraplegia due to certain types of spinal cord injury to stand up, sit down, and walk, with the assistance of a specially trained companion.
Emerging Technology Reports
The Emerging Technology Report provides regular updates about emerging and potentially disruptive technologies that are likely to have a significant impact in healthcare. This “early warning” report monitors new health technologies from 6 months to 2 years within a regulatory submission and tracks those as they go through clinical trial development and the regulatory approval process.
For each emerging technology, our analysts describe the technology and intended use, its prospects relative to the regulatory process and FDA information, competing technologies, relevant clinical guidelines, high-level look at the evidence such as published abstracts in the medical literature and available meeting abstracts, and available clinical trials.
Esbriet (Pirfenidone)
An oral drug for the treatment of idiopathic pulmonary fibrosis.
Cerena Single-Pulse Transcranial Magnetic Stimulator
A noninvasive device for the acute treatment of pain due to migraine headache with aura.
InterVapor System for Bronchoscopic Thermal Vapor Ablation (BTVA)
A device delivering localized thermal energy to target lung segments, used as an alternative to lung volume reduction surgery for palliative treatment of heterogeneous emphysema.
Dalvance (Dalbavancin)
An intravenous semisynthetic lipoglycopeptide antibiotic administered in a 2-dose regimen to treat acute bacterial skin and skin structure infections in adults.
Belsomra (Suvorexant; Formerly MK-4305)
A new oral drug for the treatment of insomnia.
Perjeta (Pertuzumab) for Neoadjuvant Treatment of Early-Stage Breast Cancer
An intravenous agent for neoadjuvant treatment of human epidermal receptor 2 (HER2)-positive locally advanced, inflammatory, or early-stage breast cancer, in combination with trastuzumab and docetaxel.
Perjeta (Pertuzumab) for First-Line Treatment for HER2-Positive Metastatic Breast Cancer
An intravenous agent for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer in combination with trastuzumab and docetaxel.
Xtandi (Enzalutamide) for mCRPC in Chemotherapy-Naïve Men
A once-daily oral androgen receptor inhibitor for treatment of metastatic castration-resistant prostate cancer in chemotherapy-naive men.
Contrave (Formerly NB32; Sustained-Release Bupropion and Naltrexone)
An oral combination drug to promote long-term weight management.